months pre- and post-index periods. Patients with diabetic peripheral neuropathic pain (DPNP) or depression in the 12 months pre-index period were excluded. Each patient was classified in the duloxetine or pregabalin cohort based on the initial agent. Pre-bagalin cohort was constructed via propensity scoring controlling for differences in demographics, associated clinical and economic characteristics, and pre-index medication patterns. Medication compliance (i.e., medication possession ratio (MPR) and proportion of patients with MPR≥80%) and health care costs over the 12 months post-index period were examined between cohorts. RESULTS: Both the duloxetine (n = 3711) and pregabalin (n = 4111) cohorts had a mean age of 50 years. Many duloxetine and pregabalin patients had neuropathic pain other than DPNP (69.1% vs. 69.1%), low back pain (61.9% vs. 62.1%), cardiovascular disease (55.1% vs. 55.1%), hypertension (44.9% vs. 43.0%), and headache (36.0% vs. 35.3%), and used opioids (75% vs. 86%). Controlling for demographics, pre-index clinical and economic characteristics, and prior medication history, duloxetine patients had significantly higher MPR (0.66 vs. 0.50, p < 0.05), higher proportion of patients with MPR≥80% (47% vs. 28%, p < 0.05), and significantly lower total health care costs ($19,378 vs. $27,045, p < 0.05) over the 12 months follow-up period than pregabalin patients. CONCLUSIONS: Fibromyalgia patients treated with duloxetine had significantly higher medication compliance, but significantly lower direct health care costs than those on pregabalin. 

PM558

GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES
Claus V1, Steinle T2, Kostev K3, Intorcia M4
IMS Health GmbH & Co. OHG, Munich, Germany, 1Amgen Germany GmbH, Munich, Germany, 2IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany, 3Amgen Europe GmbH, Zülpich, Germany

OBJECTIVES: To describe the adherence for different treatment regimens of oral bis phosphonates (oBP) in osteoporosis patients in Germany. METHODS: Analyses used IMS® Disease Analyser database (contains representative information on 4130 patients receiving daily oBP treatment. In addition, a high proportion of patients discontinued/switched oBP regimens during the first year: 90.4% (daily), 71.6% (weekly) and 70.6% (monthly). CONCLUSIONS: The majority of patients were receiving weekly oBP therapy. Compliance varied for the different treatment regimens, but was particularly poor in patients receiving daily oBP treatment. In addition, a high proportion of patients discontinued/switched oBP regimens during the first year. This study provides further evidence of poor adherence in patients with osteoporosis receiving oBP therapy.

PM569

ITEM REDUCTION AND VALIDATION OF A NEW ADHERENCE QUESTIONNAIRE IN OSTEOPOROTIC POST-MENOPAUSAL WOMEN: THE ADHERENCE EVALUATION OF OSTEOPOROSIS TREATMENT (ADEOS) QUESTIONNAIRE
Cortez B1, Bay C2, Bruel V1, Reynaert A1, Diaz-Barbosa C4, Roborel de Clemans A1, Gaudin AP5, Courtte F6
CHRU Lille, Lille, France, 1CHU Angers, France, 2CHU de Nice, Nice, France, 3Mapi Values, France, Lyon, France, 4Mapi Values, Lyon, France, 5Gáveo SmithKline France, Marly le Roi, France

OBJECTIVES: To reduce and validate the ADEOS questionnaire, an instrument specifically developed to evaluate treatment adherence by women with postmenopausal osteoporosis. METHODS: The ADEOS questionnaire has been developed with clinicians and patients. Before item reduction, it included 45 items covering 5 distinct themes related to adherence (personal characteristics, beliefs, perceptions, behaviour and information received). It was included for finalisation and validation in a cross-sectional observational study in French general practitioners. The study sample was randomly divided into 2 subsamples: one for item selection, one for validation. The item selection process was performed according to the association of the items with the generic measure of compliance, the Morisky Medication Adherence Scale (MMAS). The validity of the score derived from these items was assessed by its correlation with MMAS score. Its ability to separate compliant patients from non-compliant patients according to MMAS was studied using area under receiver-operator characteristic curve (AUC). RESULTS: Five hundred sixty osteoporotic women were included, of whom 348 (62%) returned the ADEOS questionnaire. Patients who did not return the questionnaire were comparable to those who did in terms of demographic, adherence and medical parameters. The questionnaire quality of completion was very good, confirming its good acceptability. Twelve items of the questionnaire showed a statistically significant relationship (p<0.05) with the MMAS in the “item selection sample” (N=200) and were retained to derive the ADEOS score. In the “validation sample” (N=148), the ADEOS score was noticeably correlated with MMAS score (Spearman correlation coefficient: 0.58) and showed good discriminant validity according to MMAS (AUC: 0.84). CONCLUSIONS: The 12-item ADEOS questionnaire is a short validated instrument specific to osteoporosis, whose score can easily be calculated by hand. Therefore, it might be particularly useful in daily practice to detect patients at risk of being poorly adherent to their osteoporotic treatment.

PM570

USE OF QUALITATIVE RESEARCH TO ELICIT PATIENT-REPORTED OUTCOME APPROACHES IN OSTEOPOROSIS
Aigle P1, Murant C2, Vigneux M1, Seigobis E1
1Server, Suresnes, France, 2Mapi Values, Lyon, France

OBJECTIVES: Recent anti-osteoporotic treatments are characterised by monthly or even yearly administration. These treatments may challenge the prescription of daily-administered drugs. The objective of this qualitative research was to explore patients' perception as well as clinicians' views on the frequency of anti-osteoporotic treatment administration. METHODS: A health psychologist carried out face-to-face interviews with six patients treated on a daily basis and six patients treated with a monthly-administered drug. The patients' perception, behaviour and expectations regarding anti-osteoporotic treatment were assessed. Clinicians who recruited the patients, comprising a general practitioner and specialists, were also interviewed. Information on patients feedback and perception in their decision was collected. RESULTS: Patients perceived osteoporosis as a sign of premature ageing and a disease of secondary importance. They reported that a daily administration was not a problem per se if it did not modify their lifestyle. They raised concerns about the increased risk of fracture frequency. Clinicians did not feel the difficulty of remembering to take the treatment; the worry about the treatment being too concentrated, with the thought of a possible irregular efficacy of the drug over the time and a harmful effect. They did not feel involved in the choice of treatment. Clinicians believed monthly administration to be more convenient than daily administration. They declared choosing the treatment according to the patient's characteristics, in particular concomitant diseases, lifestyle, and dosing preference. CONCLUSIONS: Discrepancies exist between clinicians' perception and reality for patients' regarding anti-osteoporotic treatment. Consequently, possible patient-reported outcomes approaches to improve treatment-decision would consist in 1) educating patients on osteoporosis, and clinicians on their patients' perception and expectations, and 2) promoting shared decision-making. This is likely to contribute to a better persistence of the patients with regard to their treatment.

PM571

PREDICTING CHANGES IN EQ-SD UTILITY SCORE VIA PASI OR HAQ IN PSORIATIC ARTHRITIS PATIENTS
Zbrozek A1, Kirkham B2, Li W1, Molta C3, Singh A1
1Wyeth Research, Philadelphia, PA, USA, 2University of New South Wales, Sydney, NSW, Australia

OBJECTIVES: To compare the predictive power post hoc of skin signs and physical function in improvement of health state utility scores in a population with active psoriatic arthritis (PsA). METHODS: A 12-week randomized double-blind study followed by a 12-week open-label extension; subjects received etanercept 50 mg BIW or 50 mg QW during the double-blind period; followed by 50 mg QW during the open-label period. Eligibility criteria included: age ≥18 y; stable, moderate-to-severe plaque psoriasis with ≥25 swollen/painful joints. PASI for psoriasis signs, HAQ for physical function, and EQ-SD were measured at baseline, Weeks 12 and 24. Logistic regression was used to predict the minimally clinically meaningful change in EQ-SD of at least 0.05 (95% CI, 0.035–0.105). Meanings changes were derived from baseline as predictors: HAQ = 0.375, 0.5; PASI = 50%, 75%. RESULTS: At baseline, subjects (n = 752) had a mean age 47 y, were 63% male, and 89% white. Mean number of tender joints =19.2, and swollen joints =12.5. Mean durations of psoriasis and psoriatic arthritis >7 years, respectively. Baseline scores were not significantly different between the 2 groups; pooled baseline (mean ± s.d.) PASI = 19.4±10.28, HAQ = 0.91±0.69, and EQ-SD = 0.48±0.32. Only PASI change from baseline at Week 12 differentiated treatment groups. Pooled reductions from baseline to Week 24 (LOCQ) were: PASI = 75.9%, HAQ = 52.0%. Proportion achieving EQ-SD (20.05) ≥74.6%. HAQ changes from baseline were stronger predictors of pre-determined changes in EQ-SD utility scores than PASI changes, with HAQ change ≥20.375 at Week 24 being the strongest single change predictor (OR = 4.36 [2.01–9.44]). Higher baseline HAQ scores reduced the odds 0.12 (0.07–0.20), and 0.19 (0.11–0.31) for minimally meaningful health status improvements at Weeks 12 and 24, respectively. CONCLUSIONS: Patients with less advanced PsA could have better odds of meaningful improvement in health status when treated to reduce both skin and joint morbidity.

PM572

A CALIBRATION OF THE RELATIONSHIP BETWEEN THE HQ, THE SF-6D AND THE EQ-SD IN INFLAMMATORY ARTHRITIS
Adams R1, Walsh C2, Tilson L1, FitzGerald O3, Bresnihan B3, Veale D3, Barry M1
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 3St Vincent's University Hospital, Dublin, Ireland

OBJECTIVES: To examine the relationship between disease-specific measure, Health Assessment Questionnaire (HAQ) disability index (DI) and the preference-based measures, Short Form-6D (SF-6D) and the EuroQol (EQ-SD) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). METHODS: Five hundred and four patients attending a rheumatology outpatient clinic with RA and PsA completed the HAQ, Short Form 36 and the EQ-SD before starting biologic therapy and 12 months after.